1[1]France G S,McDonald K M,Mrcpi M B,et al.Neurohormonal activation in preclinical heart failure: remodeling and potential for intervention[J].Circulation,1993,87(suppl IV):90.
2[2]Ferguson D W.Sympathetic mechanism in heart failure: Pathophysiological and pharmacological inplication[J].Circulation,1993,87(suppl VII):68.
3[3]Onuoha G N,Nugent A M,Hunter S J,et al.Neuropeptide variability in man (see comments)[J].Eur J Clin Invest,2000,30(7):570-577.
4[4]Navookarasu N T,Rahman A R,Abdullah I,et al.First-dose response to angiotensinconverting enzyme inhibition in congestive cardiac failure: a malaysian experience[J].Int J Clin Pract,1999,53(1):25-30.
5[5]Raiat R,Piot O,Gallolis H,et al.Blood pressure response to the first 36 hours of heart failure therapy with peridopril versus captopril.French General Hospital National College of Cardiologist[J].J Cardiovasc Pharmacol,1999,33(6):953-959.
同被引文献9
1陈灏珠.实用内科学第11版.人民卫生出版社,2001:2428.
2Ho K K,Anderson K M,Kannel W B,et al.Survival after the onset of congestive heart failure in Framingham Heart Study subjects.Circulation Jul,1993,88:107-115.
3Opasich C,Pinna GD,Mazza A,et al.Reproducibility of the six-minute walking test in patients with chronic congestive heart failure:practical implications.Am J Cardiol,1998,81:1497-1500.
